About this Journal Submit a Manuscript Table of Contents
Cholesterol
Volume 2010 (2010), Article ID 383281, 11 pages
http://dx.doi.org/10.1155/2010/383281
Clinical Study

Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease

1Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
2Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
3Global Medical Affairs, Genzyme, Cambridge, MA 02142, USA

Received 23 March 2010; Accepted 21 June 2010

Academic Editor: Serena Tonstad

Copyright © 2010 Yunsheng Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Rosamond, K. Flegal, G. Friday et al., “Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 115, no. 5, pp. e69–e171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002. View at Scopus
  3. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto, “MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. T. R. Pedersen, J. Kjekshus, K. Berg et al., “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994,” Atherosclerosis. Supplements, vol. 5, no. 3, pp. 81–87, 2004. View at Scopus
  6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels,” The New England Journal of Medicine, vol. 339, no. 19, pp. 1349–1357, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” The New England Journal of Medicine, vol. 335, no. 14, pp. 1001–1009, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Scopus
  9. P. Sackett and J. Snow, “The magnitude of compliance and noncompliance,” in Compliance in Health Care, R. Haynes, D. Taylor, and D. E. Sackett, Eds., Johns Hopkins Press, Baltimore, MD, USA, 1979.
  10. D. Sackett and R. Haynes, Compliance with Therapeutic Regimens, Johns Hopkins Press, Baltimore, MD, USA, 1976.
  11. P. G. Rogers and W. R. Bullman, “Prescription medicine compliance: a review of the baseline of knowledge—a report of the National Council on Patient Information and Education,” Journal of Pharmacoepidemiology, vol. 3, no. 2, pp. 3–36, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and J. Avorn, “Long-term persistence in use of statin therapy in elderly patients,” Journal of the American Medical Association, vol. 288, no. 4, pp. 455–461, 2002. View at Scopus
  13. J. S. Berg, J. Dischler, D. J. Wagner, J. J. Raia, and N. Palmer-Shevlin, “Medication compliance: a healthcare problem,” The Annals of Pharmacotherapy, vol. 27, no. 9, supplement, pp. S1–S24, 1993. View at Scopus
  14. S. E. Andrade, A. M. Walker, L. K. Gottlieb et al., “Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings?” The New England Journal of Medicine, vol. 332, no. 17, pp. 1125–1131, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Avorn, J. Monette, A. Lacour et al., “Persistence of use of lipid-lowering medications: a cross-national study,” Journal of the American Medical Association, vol. 279, no. 18, pp. 1458–1462, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. L. A. Simons, G. Levis, and J. Simons, “Apparent discontinuation rates in patients prescribed lipid-lowering drugs,” Medical Journal of Australia, vol. 164, no. 4, pp. 208–211, 1996. View at Scopus
  17. D. Mann, K. Reynolds, D. Smith, and P. Muntner, “Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines,” Annals of Pharmacotherapy, vol. 42, no. 9, pp. 1208–1215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Lachaine, S. Rinfret, E. P. Merikle, and J.-E. Tarride, “Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data,” American Heart Journal, vol. 152, no. 1, pp. 164–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Ma, W. Li, B. C. Olendzki et al., “Dietary quality 1 year after diagnosis of coronary heart disease,” Journal of the American Dietetic Association, vol. 108, no. 2, pp. 240–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Ockene, E. V. Wheeler, A. Adams, T. G. Hurley, and J. Hebert, “Provider training for patient-centered alcohol counseling in a primary care setting,” Archives of Internal Medicine, vol. 157, no. 20, pp. 2334–2341, 1997. View at Scopus
  21. M. C. Rosal, C. B. Ebbeling, I. Lofgren, J. K. Ockene, I. S. Ockene, and J. R. Hebert, “Facilitating dietary change: the patient-centered counseling model,” Journal of the American Dietetic Association, vol. 101, no. 3, pp. 332–341, 2001. View at Scopus
  22. J. F. Steiner and A. V. Prochazka, “The assessment of refill compliance using pharmacy records: methods, validity, and applications,” Journal of Clinical Epidemiology, vol. 50, no. 1, pp. 105–116, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Frid, I. S. Ockene, J. K. Ockene et al., “Severity of angiographically proven coronary artery disease predicts smoking cessation,” American Journal of Preventive Medicine, vol. 7, no. 3, pp. 131–135, 1991. View at Scopus
  24. J. Ockene, J. L. Kristeller, R. Goldberg et al., “Smoking cessation and severity of disease: the coronary artery smoking intervention study,” Health Psychology, vol. 11, no. 2, pp. 119–126, 1992. View at Publisher · View at Google Scholar · View at Scopus
  25. C. A. Sueta, M. Chowdhury, S. J. Boccuzzi et al., “Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease,” American Journal of Cardiology, vol. 83, no. 9, pp. 1303–1307, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. M. V. Cohen, M.-J. Byrne, B. Levine, T. Gutowski, and R. Adelson, “Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease,” Circulation, vol. 83, no. 4, pp. 1294–1304, 1991. View at Scopus
  27. M. Miller, R. Byington, D. Hunninghake, B. Pitt, and C. D. Furberg, “Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada,” Archives of Internal Medicine, vol. 160, no. 3, pp. 343–347, 2000. View at Scopus
  28. S. R. Erickson, R. Slaughter, and H. Halapy, “Pharmacists' ability to influence outcomes of hypertension therapy,” Pharmacotherapy, vol. 17, no. 1, pp. 140–147, 1997. View at Scopus
  29. J. E. Borenstein, G. Graber, E. Saltiel et al., “Physician-pharmacist comanagement of hypertension: a randomized, comparative trial,” Pharmacotherapy, vol. 23, no. 2, pp. 209–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. K. Lee, K. A. Grace, and A. J. Taylor, “Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial,” Journal of the American Medical Association, vol. 296, no. 21, pp. 2563–2571, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. M. Grundy, G. J. Balady, M. H. Criqui et al., “When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association task force on risk reduction,” Circulation, vol. 95, no. 6, pp. 1683–1685, 1997. View at Scopus